Highly Potent Antisense Oligonucleotides Locked Nucleic Acid Gapmers Targeting the SARS-CoV-2 RNA Genome
Nucleic Acid Therapeutics · 01.12.2023 · 33 (6) · 381-385
DOI: 10.1089/nat.2023.0012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 24.11.2023. Verfasst von Vita Dauksaite und 7 weiteren Autor:innen. Beteiligte Einrichtung: Einthoven Laboratory for Vascular and Regenerative Medicine, Department of Internal Medicine (Nephrology), Leiden University Medical Centre, Leiden, …. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused the current worldwide pandemic and the associated coronavirus disease 2019 with potentially lethal outcome. Although effective vaccines strongly contributed to reduce disease severity, establishing a toolbox to control current and newly emerging coronaviruses of epidemic concern requires the development of novel therapeutic compounds, to treat severely infected individuals and to prevent virus transmission. Here we present a therapeutic strategy targeting the SARS-CoV-2 RNA genome using antisense oligonucleotides (ASOs). We demonstrate that selected locked nucleic acid gapmers have the potency to reduce the in vitro intracellular viral load by up to 96%. Our promising results strongly support the case for further development of our preselected ASOs as therapeutic or prophylactic antiviral agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Einthoven Laboratory for Vascular and Regenerative Medicine, Department of Internal Medicine (Nephrology), Leiden University Medical Centre, Leiden, The Netherlands.
- Department of Medical Microbiology, Leiden University Medical Centre, Leiden, The Netherlands.
- Hybridize Therapeutics, Oegstgeest, The Netherlands.
ORCID-Profile: Anton Jan van Zonneveld
Zitieren
APA
Dauksaite, V., Tas, A., Wachowius, F., Spruit, A., van Hemert, M. J., Snijder, E. J., van der Veer, E. P., & van Zonneveld, A. J. (2023). Highly Potent Antisense Oligonucleotides Locked Nucleic Acid Gapmers Targeting the SARS-CoV-2 RNA Genome. Nucleic Acid Therapeutics, 33(6), 381-385. https://doi.org/10.1089/nat.2023.0012
Vancouver
Dauksaite V, Tas A, Wachowius F, Spruit A, van Hemert MJ, Snijder EJ, et al. Highly Potent Antisense Oligonucleotides Locked Nucleic Acid Gapmers Targeting the SARS-CoV-2 RNA Genome. Nucleic Acid Therapeutics. 2023;33(6):381-385. doi:10.1089/nat.2023.0012
BibTeX
@article{Dauksaite2023,
author = {Dauksaite, Vita and Tas, Ali and Wachowius, Falk and Spruit, Anouk and van Hemert, Martijn J and Snijder, Eric J and van der Veer, Eric P and van Zonneveld, Anton Jan},
title = {Highly Potent Antisense Oligonucleotides Locked Nucleic Acid Gapmers Targeting the SARS-CoV-2 RNA Genome},
journal = {Nucleic Acid Therapeutics},
year = {2023},
volume = {33},
number = {6},
pages = {381--385},
doi = {10.1089/nat.2023.0012}
}
EUVIMED